JUPITER NEUROSCIENCES, INC.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
JUNS$2.22+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| For the Six Months Ended · For the Six Months Ended | |||
|---|---|---|---|
| June 30, 2026 · June 30, 2025 | |||
| Cash Flows from Operating Activities: | |||
| Net Loss | $(4,336,355) | $(3,781,832) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Gain on change in fair value of convertible notes | (550,380) | - | |
| Interest expense paid through sale of common stock | 131,479 | - | |
| Amortization of prepaid contracts | 380,183 | 380,182 | |
| Stock-based compensation | 991,989 | 883,942 | |
| Shares issued for services | - | 66,000 | |
| Change in operating lease right of use asset and lease liabilities | 2,710 | (1,908) | |
| Decreases (increases) in operating assets and liabilities: | |||
| Accounts receivable | (7,604) | - | |
| Prepaid contracts | - | (60,132) | |
| PharmAla escrow deposit -other assets | (600,000) | - | |
| Inventory | 24,500 | - | |
| Other assets | (22,467) | - | |
| Accounts payable and accrued expenses | 279,597 | 177,481 | |
| Accrued compensation | 16,680 | 442,826 | |
| Deferred revenue | 124 | ||
| Refund liability | 2,351 | ||
| Accrued interest | (39,829) | 2,178 | |
| Net cash used in operating activities | (3,727,022) | (1,891,263) | |
| Cash Flows from Financing Activities: | |||
| Proceeds from exercise of stock options | 5,507 | - | |
| Payment on convertible note payable | (405,953) | - | |
| Proceeds from offering, net of costs | 1,860,000 | - | |
| Net cash provided by financing activities | 1,459,554 | - | |
| Net Change in Cash | (2,267,468) | (1,891,263) | |
| Beginning of period | 3,789,342 | 3,769,510 | |
| End of period | $1,521,874 | $1,878,247 | |
| Supplemental disclosure of cash flow information: | |||
| Cash paid for interest | $87,154 | $186 | |
| Operating lease right-of-use asset obtained in exchange for operating lease liability | $222,796 | $ | - |
| Schedule of Non-Cash Investing and Financing Activities: | |||
| Payment of convertible note from issuance of common stock | $2,813,265 | $ | - |
| Stock issued in connection with interest payment | $125,426 | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.